Genentech Dodges FCA Claims Over Avastin's Side Effects
A New Jersey federal judge on Thursday dismissed a False Claims Act against Genentech Inc. regarding its cancer drug Avastin, holding a whistleblower didn't show the drug's advertised claims were false...To view the full article, register now.
Already a subscriber? Click here to view full article